---
created: '2026-02-08T19:25:12.988655Z'
description: Class IA antiarrhythmic agent used for atrial and ventricular arrhythmias.
  Also an antimalarial agent.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/Drug/quinidine/
slug: quinidine
tags:
- Drug
- drug
- antiarrhythmic
- antimalarial
- ion_channel_blocker
- imported
- primekg
title: Quinidine
type: Drug
updated: '2026-02-08T19:25:12.988655Z'
---

# Quinidine

## Overview
Quinidine is the optical isomer of Quinine (from Cinchona bark). It is a **Class IA antiarrhythmic** that stabilizes cardiac membranes. While historically important for maintaining sinus rhythm in atrial fibrillation, its use has declined due to pro-arrhythmic side effects (Torsades de Pointes) and the availability of safer alternatives.

It is also a potent inhibitor of **CYP2D6** and P-glycoprotein, making it a source of significant drug interactions. It is notably used in the Nuedexta combination (Dextromethorphan/Quinidine) solely to block the metabolism of Dextromethorphan.

## Indications
- **Atrial Fibrillation/Flutter**: Cardioversion maintenance (historical).
- **Ventricular Arrhythmias**: Treatment.
- **Malaria**: Severe P. falciparum infection (IV).
- **Pseudobulbar Affect**: As a booster for Dextromethorphan.
- **Brugada Syndrome**: Prevention of V-fib storms.

<!-- NEO4J_CONTENT_START -->
## Relationships
### Related
- ← [[Atrial_Fibrillation]] (condition)
```yaml
last_modified: '2026-01-26T06:47:31.355660'
source: obsidian
```
- → [[Atrial_Fibrillation]] (condition)
```yaml
last_modified: '2026-01-26T07:07:43.728314'
source: obsidian
```
- → [[Aluminium_phosphate]] (entity)
```yaml
last_modified: '2026-01-26T06:48:01.183339'
source: obsidian
```
- → [[QT_Prolongation]] (entity)
```yaml
last_modified: '2026-01-26T06:48:01.183339'
source: obsidian
```
- → [[Sodium_Channel]] (entity)
```yaml
last_modified: '2026-01-26T06:48:01.183339'
source: obsidian
```
- → [[Indigotindisulfonic_acid]] (entity)
```yaml
last_modified: '2026-01-26T06:48:01.183339'
source: obsidian
```
- → [[Magnesium_glycinate]] (entity)
```yaml
last_modified: '2026-01-26T06:48:01.183339'
source: obsidian
```
- → [[Torsades_de_Pointes]] (entity)
```yaml
last_modified: '2026-01-26T06:48:01.183339'
source: obsidian
```
- → [[Magnesium_aspartate]] (entity)
```yaml
last_modified: '2026-01-26T06:48:01.183339'
source: obsidian
```
- → [[Potassium_Channel]] (entity)
```yaml
last_modified: '2026-01-26T06:48:01.183339'
source: obsidian
```
- → [[Magnesium_peroxide]] (entity)
```yaml
last_modified: '2026-01-26T06:48:01.183339'
source: obsidian
```
- → [[Brugada_Syndrome]] (entity)
```yaml
last_modified: '2026-01-26T06:48:01.183339'
source: obsidian
```
- → [[Atrial_Fibrillation]] (entity)
```yaml
last_modified: '2026-01-26T06:48:01.183339'
source: obsidian
```
- → [[Acetylglycinamide_chloral_hydrate]] (entity)
```yaml
last_modified: '2026-01-26T06:48:01.183339'
source: obsidian
```
- → [[Brugada_Syndrome]] (entity)
```yaml
last_modified: '2026-01-26T07:07:43.728314'
source: obsidian
```
- → [[Potassium_Channel]] (entity)
```yaml
last_modified: '2026-01-26T07:07:43.728314'
source: obsidian
```
- → [[P-glycoprotein]] (entity)
```yaml
last_modified: '2026-01-26T07:07:43.728314'
source: obsidian
```
- → [[Malaria]] (entity)
```yaml
last_modified: '2026-01-26T07:07:43.728314'
source: obsidian
```
- → [[QT_Prolongation]] (entity)
```yaml
last_modified: '2026-01-26T07:07:43.728314'
source: obsidian
```
- → [[Torsades_de_Pointes]] (entity)
```yaml
last_modified: '2026-01-26T07:07:43.728314'
source: obsidian
```
- → [[Cinchonism]] (entity)
```yaml
last_modified: '2026-01-26T07:07:43.728314'
source: obsidian
```
- → [[CYP2D6]] (entity)
```yaml
last_modified: '2026-01-26T07:07:43.728314'
source: obsidian
```
- → [[Sodium_Channel]] (entity)
```yaml
last_modified: '2026-01-26T07:07:43.728314'
source: obsidian
```
- → [[Arrhythmia]] (entity)
```yaml
last_modified: '2026-01-26T07:07:43.728314'
source: obsidian
```

### Interactswith
- ← [[Magnesium_peroxide]] (entity)
```yaml
imported: '2025-12-26T11:56:35.240000+00:00'
source: PrimeKG
```
- ← [[Aluminium_phosphate]] (entity)
```yaml
imported: '2025-12-26T11:56:35.296000+00:00'
source: PrimeKG
```
- ← [[Magnesium_aspartate]] (entity)
```yaml
imported: '2025-12-26T11:56:35.354000+00:00'
source: PrimeKG
```
- ← [[Magnesium_glycinate]] (entity)
```yaml
imported: '2025-12-26T11:56:35.405000+00:00'
source: PrimeKG
```
- ← [[Acetylglycinamide_chloral_hydrate]] (entity)
```yaml
imported: '2025-12-26T11:56:35.449000+00:00'
source: PrimeKG
```
- ← [[Indigotindisulfonic_acid]] (entity)
```yaml
imported: '2025-12-26T11:56:35.471000+00:00'
source: PrimeKG
```
<!-- NEO4J_CONTENT_END -->
## Relationships

### Modulates Protein
- ⊣ [[Sodium Channel]] (protein) - *Blocks INa (Phase 0)*
- ⊣ [[Potassium Channel]] (protein) - *Blocks IKr (Phase 3 - QT prolongation)*
- ⊣ [[CYP2D6]] (protein) - *Potent Inhibitor*
- ⊣ [[P-glycoprotein]] (protein) - *Inhibitor*

### Treats Condition
- → [[Arrhythmia]] (condition)
- → [[Atrial Fibrillation]] (condition)
- → [[Malaria]] (condition)
- → [[Brugada Syndrome]] (condition)

### Adverse Effects
- → [[QT Prolongation]] (condition)
- → [[Torsades de Pointes]] (condition)
- → [[Cinchonism]] (condition) - *Tinnitus, headache, visual changes*

## References
1. **Mechanism**: Grace, A. A., & Camm, A. J. (1998). "Quinidine." *European Heart Journal*.
2. **Brugada Syndrome**: Belhassen, B., et al. (2004). "Efficacy of quinidine in high-risk patients with Brugada syndrome." *Circulation*.